Drug and biotech companies join lobbying push on China bill as scrutiny of WuXi continues
Almost 20 biopharma and life sciences companies have registered to lobby on a bill that could ban US companies from working with Chinese life sciences contractors, according to federal records.
Since the Biosecure Act was introduced in January, most healthcare companies have steered away from publicly commenting on it. But as the proposal slowly advances in Congress — and as the consequences of a ban on WuXi Apptec, WuXi Biologics and genomics companies like BGI have come into focus — companies in recent months launched lobbying efforts on the bill.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
